Clofazimine Soft Capsules, a national exclusive product, It is used in the treatment of multidrug-resistant tuberculosis (MDR -- TB) and extensively drug-resistant tuberculosis (XDR -- TB), and was successfully granted a patent certificate by the state in 2013. Due to its remarkable therapeutic effect in a wide range of clinical applications, it has attracted great attention from the state, and was supported by the national special fund in 2010.